标题
ATM-Deficient Cancers Provide New Opportunities for Precision Oncology
作者
关键词
-
出版物
Cancers
Volume 12, Issue 3, Pages 687
出版商
MDPI AG
发表日期
2020-03-19
DOI
10.3390/cancers12030687
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Targeting Mitochondrial Apoptosis to Overcome Treatment Resistance in Cancer
- (2020) Natalie Yan Li Ngoi et al. Cancers
- Molecular Mechanisms of Radiation-Induced Cancer Cell Death: A Primer
- (2020) Joseph Sia et al. Frontiers in Cell and Developmental Biology
- Targeting apoptotic caspases in cancer
- (2020) Ashley Boice et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks
- (2019) Gabriel Balmus et al. Nature Communications
- Structural basis of allosteric regulation of Tel1/ATM kinase
- (2019) Jiyu Xin et al. CELL RESEARCH
- Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand
- (2019) Lin Mei et al. Journal of Hematology & Oncology
- Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
- (2019) Kathleen N Moore et al. LANCET ONCOLOGY
- A decade of clinical development of PARP inhibitors in perspective
- (2019) J Mateo et al. ANNALS OF ONCOLOGY
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
- (2019) Talia Golan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Defining and Modulating ‘BRCAness’
- (2019) Andrea K. Byrum et al. TRENDS IN CELL BIOLOGY
- Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells
- (2019) Nicholas R. Jette et al. BRITISH JOURNAL OF CANCER
- Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant
- (2019) Jennifer K. Litton et al. JOURNAL OF CLINICAL ONCOLOGY
- Near-Complete Structure and Model of Tel1ATM from Chaetomium thermophilum Reveals a Robust Autoinhibited ATP State
- (2019) Marijke Jansma et al. STRUCTURE
- Cryo-EM Structure of Nucleotide-Bound Tel1ATM Unravels the Molecular Basis of Inhibition and Structural Rationale for Disease-Associated Mutations
- (2019) Luke A. Yates et al. STRUCTURE
- PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells
- (2019) Sylvie M. Noordermeer et al. TRENDS IN CELL BIOLOGY
- Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
- (2019) Joaquin Mateo et al. LANCET ONCOLOGY
- Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?
- (2019) Alice Bradbury et al. PHARMACOLOGY & THERAPEUTICS
- PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials
- (2018) Dalia Kamel et al. CURRENT DRUG TARGETS
- Homologous recombination and the repair of DNA double-strand breaks
- (2018) William Douglass Wright et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
- (2018) Alan Ashworth et al. Nature Reviews Clinical Oncology
- Mechanisms of PARP inhibitor sensitivity and resistance
- (2018) Alan D. D’Andrea DNA REPAIR
- High speed of fork progression induces DNA replication stress and genomic instability
- (2018) Apolinar Maya-Mendoza et al. NATURE
- State-of-the-art strategies for targeting the DNA damage response in cancer
- (2018) Patrick G. Pilié et al. Nature Reviews Clinical Oncology
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- DNA Repair in Prostate Cancer: Biology and Clinical Implications
- (2017) Joaquin Mateo et al. EUROPEAN UROLOGY
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Robert L Coleman et al. LANCET
- AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells
- (2017) Ahrum Min et al. MOLECULAR CANCER THERAPEUTICS
- ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response
- (2017) Andrew N. Blackford et al. MOLECULAR CELL
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib
- (2017) Chen Wang et al. Translational Oncology
- Accelerating Discovery of Functional Mutant Alleles in Cancer
- (2017) Matthew T. Chang et al. Cancer Discovery
- Modulating Both Tumor Cell Death and Innate Immunity Is Essential for Improving Radiation Therapy Effectiveness
- (2017) Qiuji Wu et al. Frontiers in Immunology
- A new role for ATM in selective autophagy of peroxisomes (pexophagy)
- (2016) Durga Nand Tripathi et al. Autophagy
- Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA -Mutant Ovarian Cancer Models
- (2016) Hyoung Kim et al. CLINICAL CANCER RESEARCH
- The repair capacity of lung cancer cell lines A549 and H1299 depends on HMGB1 expression level and thep53status
- (2016) Shazie Yusein-Myashkova et al. JOURNAL OF BIOCHEMISTRY
- ATM Mutations in Cancer: Therapeutic Implications
- (2016) M. Choi et al. MOLECULAR CANCER THERAPEUTICS
- Ataxia telangiectasia: a review
- (2016) Cynthia Rothblum-Oviatt et al. Orphanet Journal of Rare Diseases
- ATM protein is deficient in over 40% of lung adenocarcinomas
- (2016) Liza C. Villaruz et al. Oncotarget
- The interplay between DNA repair and autophagy in cancer therapy
- (2015) Dan Zhang et al. CANCER BIOLOGY & THERAPY
- The same, only different - DNA damage checkpoints and their reversal throughout the cell cycle
- (2015) I. A. Shaltiel et al. JOURNAL OF CELL SCIENCE
- Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer
- (2015) Yung-Jue Bang et al. JOURNAL OF CLINICAL ONCOLOGY
- Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity
- (2015) Matthew T Chang et al. NATURE BIOTECHNOLOGY
- ATM functions at the peroxisome to induce pexophagy in response to ROS
- (2015) Jiangwei Zhang et al. NATURE CELL BIOLOGY
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo
- (2015) Frank P. Vendetti et al. Oncotarget
- A Systematic Analysis of Factors Localized to Damaged Chromatin Reveals PARP-Dependent Recruitment of Transcription Factors
- (2015) Lior Izhar et al. Cell Reports
- Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines
- (2014) Eiji Kubota et al. CELL CYCLE
- Having Pancreatic Cancer with Tumoral Loss of ATM and Normal TP53 Protein Expression Is Associated with a Poorer Prognosis
- (2014) H. Kim et al. CLINICAL CANCER RESEARCH
- ATM: Expanding roles as a chief guardian of genome stability
- (2014) Yosef Shiloh EXPERIMENTAL CELL RESEARCH
- Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond
- (2013) Nicola J. Curtin et al. MOLECULAR ASPECTS OF MEDICINE
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3
- (2012) William H. Chappell et al. CELL CYCLE
- Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53
- (2012) Chris T. Williamson et al. EMBO Molecular Medicine
- The Heterochromatic Barrier to DNA Double Strand Break Repair: How to Get the Entry Visa
- (2012) Aaron A. Goodarzi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Discovery of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer Agents
- (2011) Jean-Damien Charrier et al. JOURNAL OF MEDICINAL CHEMISTRY
- The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
- (2011) Thomas Helleday Molecular Oncology
- Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR
- (2011) Philip M Reaper et al. Nature Chemical Biology
- The ATM protein kinase and cellular redox signaling: beyond the DNA damage response
- (2011) Scott Ditch et al. TRENDS IN BIOCHEMICAL SCIENCES
- ATM Mutations in Patients with Hereditary Pancreatic Cancer
- (2011) Nicholas J. Roberts et al. Cancer Discovery
- The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo
- (2010) V. J. Weston et al. BLOOD
- Site-specific Phosphorylation Dynamics of the Nuclear Proteome during the DNA Damage Response
- (2010) Martin V. Bennetzen et al. MOLECULAR & CELLULAR PROTEOMICS
- ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors
- (2010) C. T. Williamson et al. MOLECULAR CANCER THERAPEUTICS
- The DNA Damage Response: Making It Safe to Play with Knives
- (2010) Alberto Ciccia et al. MOLECULAR CELL
- COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
- (2010) S. A. Forbes et al. NUCLEIC ACIDS RESEARCH
- The combined status of ATM and p53 link tumor development with therapeutic response
- (2009) H. Jiang et al. GENES & DEVELOPMENT
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin
- (2008) B. Evers et al. CLINICAL CANCER RESEARCH
- A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity
- (2008) Christopher J. Lord et al. DNA REPAIR
- A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor
- (2008) Nicholas C Turner et al. EMBO JOURNAL
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now